Rhinitis Drug Pipeline Analysis Report 2025
Description
Allergic rhinitis is an inflammatory condition of the nasal passages, commonly triggered by allergens like pollen, dust mites, and pet dander. It affects over 400 million people globally, with prevalence rates ranging from 10% to 30% in adults and over 40% in children. Despite existing treatment options, such as antihistamines and intranasal corticosteroids, a high unmet clinical need remains for more effective therapies. Current treatments often offer limited relief, prompting ongoing research into novel approaches, including biologics and targeted therapies. The increasing focus on precision medicine and immunotherapies is expected to drive significant growth in the rhinitis drug pipeline in the coming years.
Report Coverage
The Rhinitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into rhinitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for rhinitis. The rhinitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The rhinitis pipeline landscape will include an analysis based on efficacy and safety measures published for the trials, including their adverse effects on patients suffering from the condition, and alignment with rhinitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to rhinitis.
Rhinitis Drug Pipeline Outlook
Rhinitis is an inflammation of the nasal mucosa, often triggered by allergens such as pollen, dust, and pet dander. It leads to symptoms like sneezing, congestion, and a runny nose. The condition is widespread, affecting both adults and children. It occurs when the immune system overreacts to harmless substances, releasing histamines and other chemicals that cause inflammation.
Rhinitis treatment focuses on symptom relief through antihistamines, nasal corticosteroids, and decongestants. Immunotherapy and biologics are emerging options for severe cases. However, current therapies provide only partial relief, highlighting the need for more effective and targeted treatments.
Rhinitis Epidemiology
Allergic rhinitis is a significant global health concern, affecting over 400 million individuals, with prevalence rates ranging from 10% to 30% among adults and over 40% among children. Epidemiological studies highlight varying allergic rhinitis prevalence, such as 24.2% in Madinah (children) and 43.8% in Riyadh (adolescents). In China, regional prevalence ranges from 6.1% in Guangzhou to 19.1% in Baoding.
Rhinitis Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of rhinitis drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total rhinitis clinical trials.
Rhinitis Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the rhinitis pipeline analysis include small molecules, monoclonal antibodies, biologics, peptides, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for rhinitis.
Rhinitis Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR rhinitis report insights include the profiles of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in rhinitis clinical trials:
This section covers a detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for rhinitis. It includes product descriptions, trial IDs, study types, drug classes, modes of administration, and recruitment statuses of rhinitis drug candidates.
Drug: Fexofenadine HCL and pseudoephedrine HCL
The Phase IV clinical trial sponsored by Sanofi aims to assess the safety and efficacy of the Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL fixed-dose combination in Indian participants with allergic rhinitis aged 12 and above. The study, expected to be completed by October 30, 2025, will enroll approximately 203 participants, and evaluate the drug's effectiveness using nasal symptoms and total symptom scores.
Biological: MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL)
Inmunotek S.L. is sponsoring a Phase 3 clinical trial to assess the efficacy and safety of subcutaneous immunotherapy for mild to moderate asthma and rhinitis/rhinoconjunctivitis triggered by dust mite allergies. The trial will include 400 participants and is expected to conclude by July 2025. Its primary objective is to evaluate symptom scores and medication usage in managing the conditions.
Drug: INI-2004
Sponsored by Inimmune Corporation, this Phase I clinical trial investigates the safety and tolerability of INI-2004 in healthy volunteers and allergic rhinitis patients. The study aims to assess the effects of single and multiple ascending doses. The trial will involve 68 participants and is expected to conclude by November 2024.
Reasons To Buy This Report
The Rhinitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for rhinitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within rhinitis pipeline insights.
Key Questions Answered in the Rhinitis – Pipeline Insight Report
Allergic Rhinitis Market
Global Clinical Trials Market
Report Coverage
The Rhinitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into rhinitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for rhinitis. The rhinitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The rhinitis pipeline landscape will include an analysis based on efficacy and safety measures published for the trials, including their adverse effects on patients suffering from the condition, and alignment with rhinitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to rhinitis.
Rhinitis Drug Pipeline Outlook
Rhinitis is an inflammation of the nasal mucosa, often triggered by allergens such as pollen, dust, and pet dander. It leads to symptoms like sneezing, congestion, and a runny nose. The condition is widespread, affecting both adults and children. It occurs when the immune system overreacts to harmless substances, releasing histamines and other chemicals that cause inflammation.
Rhinitis treatment focuses on symptom relief through antihistamines, nasal corticosteroids, and decongestants. Immunotherapy and biologics are emerging options for severe cases. However, current therapies provide only partial relief, highlighting the need for more effective and targeted treatments.
Rhinitis Epidemiology
Allergic rhinitis is a significant global health concern, affecting over 400 million individuals, with prevalence rates ranging from 10% to 30% among adults and over 40% among children. Epidemiological studies highlight varying allergic rhinitis prevalence, such as 24.2% in Madinah (children) and 43.8% in Riyadh (adolescents). In China, regional prevalence ranges from 6.1% in Guangzhou to 19.1% in Baoding.
Rhinitis Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of rhinitis drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibodies
- Biologics
- Peptides
- Gene Therapy
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total rhinitis clinical trials.
Rhinitis Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the rhinitis pipeline analysis include small molecules, monoclonal antibodies, biologics, peptides, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for rhinitis.
Rhinitis Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR rhinitis report insights include the profiles of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in rhinitis clinical trials:
- Sanofi
- Eli Lilly and Company
- Keymed Biosciences Co. Ltd.
- Yingu Pharmaceutical Co., Ltd.
- Eurofarma Laboratorios S.A.
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Inmunotek S.L.
This section covers a detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for rhinitis. It includes product descriptions, trial IDs, study types, drug classes, modes of administration, and recruitment statuses of rhinitis drug candidates.
Drug: Fexofenadine HCL and pseudoephedrine HCL
The Phase IV clinical trial sponsored by Sanofi aims to assess the safety and efficacy of the Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL fixed-dose combination in Indian participants with allergic rhinitis aged 12 and above. The study, expected to be completed by October 30, 2025, will enroll approximately 203 participants, and evaluate the drug's effectiveness using nasal symptoms and total symptom scores.
Biological: MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL)
Inmunotek S.L. is sponsoring a Phase 3 clinical trial to assess the efficacy and safety of subcutaneous immunotherapy for mild to moderate asthma and rhinitis/rhinoconjunctivitis triggered by dust mite allergies. The trial will include 400 participants and is expected to conclude by July 2025. Its primary objective is to evaluate symptom scores and medication usage in managing the conditions.
Drug: INI-2004
Sponsored by Inimmune Corporation, this Phase I clinical trial investigates the safety and tolerability of INI-2004 in healthy volunteers and allergic rhinitis patients. The study aims to assess the effects of single and multiple ascending doses. The trial will involve 68 participants and is expected to conclude by November 2024.
Reasons To Buy This Report
The Rhinitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for rhinitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within rhinitis pipeline insights.
Key Questions Answered in the Rhinitis – Pipeline Insight Report
- What is the current landscape of rhinitis pipeline drugs?
- Which companies/institutions are developing rhinitis emerging drugs?
- How many phase II drugs are currently present in the rhinitis pipeline drugs?
- Which company is leading the rhinitis pipeline development activities?
- What is the current rhinitis therapeutic assessment?
- What are the opportunities and challenges present in the rhinitis drug pipeline landscape?
- What is the efficacy and safety profile of rhinitis pipeline drugs?
- Which companies/institutions are involved in rhinitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in rhinitis?
Allergic Rhinitis Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Rhinitis
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Rhinitis
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Rhinitis: Epidemiology Snapshot
- 5.1 Rhinitis Incidence by Key Markets
- 5.2 Rhinitis – Patients Seeking Treatment in Key Markets
- 6 Rhinitis: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Rhinitis: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Rhinitis, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Rhinitis Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Rhinitis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Fexofenadine HCL and pseudoephedrine HCL
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Biological: MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL)
- 10.2.3 Other Drugs
- 11 Rhinitis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Biological: CM310
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: TQH2722 injection
- 11.2.3 Other Drugs
- 12 Rhinitis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: INI-2004
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Rhinitis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Rhinitis, Key Drug Pipeline Companies
- 14.1 Sanofi
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Eli Lilly and Company
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Keymed Biosciences Co. Ltd.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Yingu Pharmaceutical Co., Ltd.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Eurofarma Laboratorios S.A.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Inmunotek S.L.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
